The U.S. Centers for Disease Control and Prevention said Wednesday it received reports of 28 out of 8.7 million people who developed rare blood clotting syndrome who received J & J’s Janssen coronavirus vaccine. Three of them died of the disease, known as thrombosis with thrombocytopenia syndrome (TTS).
However, during the same period – March 2 to May 7 – more than 2.2 million people were diagnosed with Covid-19 and more than 43,000 died, according to data from Johns Hopkins University.
In a group of around 8.7 million people, this rises to nearly 59,000 new cases of Covid-19 reported in the past two months and nearly 1,150 new deaths from Covid-19, more than 40 times the number of reported and confirmed cases of TTS.
According to CDC data, the chances of a person vaccinated with the J&J vaccine developing TTS are less than one in 300,000 people.
The CDC said TTS was likely linked to J & J’s Janssen vaccine, but said the benefits of the vaccine outweighed the risk nonetheless. All cases have been observed in people aged 18 to 59 years.
“Most of these TTS cases occur in the 30-49 age group,” CDC’s Dr. Tom Shimabukuro said at a meeting of the CDC’s Advisory Committee on Immunization Practices.
While most cases have been in women, six cases have been reported in men, Shimabukuro said. He said 19 had a type of cerebral blood clot called cerebral venous sinus thrombosis, or CVST, while others had different types of blood clots.
The CDC has alerted doctors and patients to the possibility of the complication so that it can be recognized and treated quickly and correctly.
“There have been no known or documented cases of a bleeding disorder,” Shimabukuro said. This indicates that it is difficult to predict who might develop the disease.
“It is important to recognize TTS early and to initiate appropriate treatment,” he added. “TTS is a rare, clinically serious and potentially fatal disease. “
TTS has also been linked to AstraZeneca’s coronavirus vaccine, which is not licensed for use in the United States but is widely used in Britain and Europe.